Loading
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
NASDAQHealthcareBiotechnology
Latest quote
$7.3105
+$0.1205 · +1.68%
Regular session
$7.3105
+$0.1205 · +1.68%
Regular session · ET · Market data may be delayed.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Day range
Current $7.3105
52-week range
Current $7.3105
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
58
Mixed
Risk
58
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Day range
Current $7.3105
52-week range
Current $7.3105
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 228K USD | 229K USD | — | — | — |
| Gross profit | −228K USD | −229K USD | — | — | — |
| Research and development | 22.96M USD | 22.82M USD | 15.81M USD | 30.08M USD | 23.97M USD |
| Selling, general, and administrative | 31.87M USD | 16.25M USD | 11.44M USD | 10.72M USD | 9.13M USD |
| Operating expenses | 54.65M USD | 38.84M USD | 27.25M USD | 40.8M USD | 33.09M USD |
| Interest income | 1.5M USD | 2.36M USD | 825K USD | 199K USD | 17K USD |
| Interest expense | 819K USD | 2.18M USD | 2.85M USD | 1.79M USD | — |
| Depreciation and amortization | 228K USD | 229K USD | 228K USD | 236K USD | 250K USD |
| Operating income | −54.88M USD | −39.07M USD | −27.25M USD | −40.8M USD | −33.09M USD |
| Net income | −54.65M USD | −39.83M USD | −29.82M USD | −42.35M USD | −33.15M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$14.80
102.45% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 31, 2020 | 1:20 | — | — |
Stock split | May 24, 2018 | 1:10 | — | — |
Stock split | Aug 3, 2017 | 1:11 | — | — |
Stock split | Aug 21, 2008 | 1:18 | — | — |
Effective Jul 31, 2020
1:20
Effective May 24, 2018
1:10
Effective Aug 3, 2017
1:11
Effective Aug 21, 2008
1:18
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI24.68M0.00%2.3T USD0.03%$380.95+0.37%
State Street SPDR S&P Biotech ETFXBI15.59M0.15%10.11B USD0.35%$151.51+1.49%
iShares Russell 2000 ETFIWM14.87M0.02%77.7B USD0.19%$278.18+0.22%
Vanguard Extended Market ETFVXF7.69M0.01%95.4B USD0.05%$234.02+0.38%
Simplify Propel Opportunities ETFSURI6.7M8.94%74.84M USD2.82%$17.08360.00%
iShares Russell 2000 Growth ETFIWO5.1M0.04%14.04B USD0.24%$354.97+0.42%
Vanguard Russell 2000 ETFVTWO3.55M0.02%18B USD0.06%$112.35+0.22%
Fidelity Enhanced Small Cap ETFFESM2.26M0.03%6.41B USD0.28%$45.33+0.18%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSimplify Propel Opportunities ETFSURIiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
